ysioscapital.com valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for ysioscapital.com:
1. POST https://agentwebmap.com/v1/sites/ysioscapital.com/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://ysioscapital.com/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/ysioscapital.com/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/ysioscapital.com).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

Ysios Capital

Backing the breakthroughs of tomorrow

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T02:43:38.583Z. Cached copy · Source on ysioscapital.com

# Ysios Capital

> Backing the breakthroughs of tomorrow

> Generated by All in One SEO Pro v5.0.3, this is an llms.txt file, used by LLMs to index the site.

## Sitemaps

- [XML Sitemap](https://ysioscapital.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [European Commission grants marketing authorisation for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease](https://ysioscapital.com/2026/09/28/european-commission-grants-marketing-authorisation-for-nezglyal-leriglitazone-the-first-pharmacological-treatment-approved-for-cerebral-adrenoleukodystrophy-cald-a-rare-neurodegenerative-d/): The first European launch is expected in Germany by the end of the year, with additional launches in Europe
- [Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer](https://ysioscapital.com/2026/09/24/ona_clinic/): Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
- [Anaconda Biomed Secures $56 Million Financing from New and Existing Investors](https://ysioscapital.com/2026/09/23/anaconda-biomed-secures-56-million-financing-from-new-and-existing-investors/): To complete the pivotal ATHENA IDE study, advance product development and support global regulatory approvals for its neurovascular portfolio.
- [Ysios Capital 2025 / H1 2026 Review](https://ysioscapital.com/2026/07/28/ysios-capital-2025-h1-2026-review/): Publication of Ysios Capital first annual review - Ysios Capital 2025 / H1 2026 Review
- [Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch](https://ysioscapital.com/2026/07/28/xeltis-raises-an-additional-e20-5m-of-funding-to-advance-axess-toward-fda-approval-and-us-commercial-launch/): Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
- [NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease](https://ysioscapital.com/2026/07/24/nezglyal-leriglitazone-receives-a-positive-chmp-opinion-for-the-treatment-of-cerebral-adrenoleukodystrophy-cald-a-rare-neurodegenerative-disease/): Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany – 24 July, 2026 – Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional
- [San Sebastián office](https://ysioscapital.com/2020/12/25/san-sebastian-office/)
- [Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline](https://ysioscapital.com/2
…

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=ysioscapital.com · GET /v1/domain/ysioscapital.com · this page as Accept: application/json or text/markdown · MCP lookup_domain